MA27021A1 - Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant - Google Patents

Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant

Info

Publication number: MA27021A1
Authority: MA; Morocco
Prior art keywords: triazatetracyclo; pentaene; hexadeca; citrate; pharmaceutical compositions
Prior art date: 2001-05-14

Application number

MA27390A

Other languages

English (en)

Inventor

Phillip James Johnson

Peter Robert Rose

Lewin Theophilus Wint

Glenn Robert Williams

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-14

Filing date

2003-11-10

Publication date

2004-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27021(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-11-10 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-12-20 Publication of MA27021A1 publication Critical patent/MA27021A1/fr

Links

KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Dermatology (AREA)
Virology (AREA)
Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Anesthesiology (AREA)
Tropical Medicine & Parasitology (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)

MA27390A 2001-05-14 2003-11-10 Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant MA27021A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29086301P	2001-05-14	2001-05-14

Publications (1)

Publication Number	Publication Date
MA27021A1 true MA27021A1 (fr)	2004-12-20

Family

ID=23117854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27390A MA27021A1 (fr)	2001-05-14	2003-11-10	Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant

Country Status (37)

Country	Link
US (1)	US6787549B2 (fr)
EP (1)	EP1390366B1 (fr)
JP (1)	JP4137645B2 (fr)
KR (1)	KR20040008175A (fr)
CN (1)	CN1509288A (fr)
AP (1)	AP1429A (fr)
AR (1)	AR035889A1 (fr)
AT (1)	ATE303386T1 (fr)
BG (1)	BG108344A (fr)
CA (1)	CA2446988A1 (fr)
CZ (1)	CZ20032917A3 (fr)
DE (1)	DE60205888T2 (fr)
DO (1)	DOP2002000390A (fr)
DZ (1)	DZ3503A1 (fr)
EA (1)	EA005529B1 (fr)
EE (1)	EE200300557A (fr)
ES (1)	ES2245731T3 (fr)
GT (1)	GT200200081A (fr)
HR (1)	HRP20030911A2 (fr)
HU (1)	HUP0304085A3 (fr)
IL (1)	IL157874A0 (fr)
IS (1)	IS6956A (fr)
MA (1)	MA27021A1 (fr)
MX (1)	MXPA03010365A (fr)
MY (1)	MY134123A (fr)
NO (1)	NO20035035D0 (fr)
NZ (1)	NZ528209A (fr)
OA (1)	OA12600A (fr)
PA (1)	PA8545001A1 (fr)
PE (1)	PE20021095A1 (fr)
PL (1)	PL366774A1 (fr)
SK (1)	SK13372003A3 (fr)
TN (1)	TNSN03112A1 (fr)
UA (1)	UA73421C2 (fr)
UY (1)	UY27287A1 (fr)
WO (1)	WO2002092597A1 (fr)
ZA (1)	ZA200307234B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS50069B (sr) *	1997-12-31	2009-01-22	Pfizer Products Inc.,	Aril kondenzovana azapoliciklična jedinjenja
WO2003045437A1 (fr)	2001-11-30	2003-06-05	Pfizer Products Inc.	Compositions pharmaceutiques de 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
WO2004103372A1 (fr) *	2003-05-20	2004-12-02	Pfizer Products Inc.	Compositions pharmaceutiques a base de varenicline
US20050043407A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of addiction in a mammal
EP2086977A2 (fr) *	2006-11-09	2009-08-12	Pfizer Products Inc.	Polymorphes d'intermédiaires nicotiniques
WO2009109651A1 (fr) *	2008-03-06	2009-09-11	Medichem, S.A.	Sels d'un dérivé de pyrazino[2,3-h][3]benzazépine
US8039620B2 (en)	2008-05-22	2011-10-18	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) *	2008-06-19	2009-12-24	Vinod Kumar Kansal	Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (fr) *	2008-07-10	2010-01-14	Teva Pharmaceutical Industries Ltd.	Procédés de purification du sel l-tartrate de varénicline et préparation de formes cristallines du sel l-tartrate de varénicline
PL2376499T3 (pl) *	2008-12-11	2015-07-31	Cti Biopharma Corp	Sól cytrynianowa 11-(2-pirrolidyn-1-yloetoksy)-14,19-dioksa-5,7,26-triazatetracyklo[19.3.1.1(2,6).1(8,12)]heptakosa-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaenu
US20100189790A1 (en)	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
WO2010143070A2 (fr)	2009-06-10	2010-12-16	Actavis Group Ptc Ehf	Co-précipités amorphes de tartrate de varénicline
EP2438054A1 (fr)	2009-06-22	2012-04-11	Teva Pharmaceutical Industries Ltd.	Formes solides des sels de varénicline et leurs procédés de préparation
WO2011140431A1 (fr)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Sels de la varénicline et leurs formes cristallines
WO2013163917A1 (fr)	2012-04-13	2013-11-07	连云港金康和信药业有限公司	Composé jk12a et sa préparation
WO2018154395A2 (fr)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Composition pharmaceutique à libération contrôlée de varénicline
EP3756653A1 (fr) *	2019-06-28	2020-12-30	Alfred E. Tiefenbacher (GmbH & Co. KG)	Citrate de varénicline à microparticules
CN115968283B (zh) *	2020-03-16	2024-11-22	成都科岭源医药技术有限公司	5-ht3受体调节剂、晶型、制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS50069B (sr) *	1997-12-31	2009-01-22	Pfizer Products Inc.,	Aril kondenzovana azapoliciklična jedinjenja
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

2002
- 2002-04-26 EE EEP200300557A patent/EE200300557A/xx unknown
- 2002-04-26 HU HU0304085A patent/HUP0304085A3/hu unknown
- 2002-04-26 DO DO2002000390A patent/DOP2002000390A/es unknown
- 2002-04-26 PL PL02366774A patent/PL366774A1/xx not_active Application Discontinuation
- 2002-04-26 CN CNA028099117A patent/CN1509288A/zh active Pending
- 2002-04-26 NZ NZ528209A patent/NZ528209A/en unknown
- 2002-04-26 EA EA200301120A patent/EA005529B1/ru not_active IP Right Cessation
- 2002-04-26 OA OA1200300290A patent/OA12600A/en unknown
- 2002-04-26 UA UA20031110265A patent/UA73421C2/uk unknown
- 2002-04-26 SK SK1337-2003A patent/SK13372003A3/sk unknown
- 2002-04-26 IL IL15787402A patent/IL157874A0/xx unknown
- 2002-04-26 CA CA002446988A patent/CA2446988A1/fr not_active Abandoned
- 2002-04-26 MX MXPA03010365A patent/MXPA03010365A/es active IP Right Grant
- 2002-04-26 DZ DZ023503A patent/DZ3503A1/fr active
- 2002-04-26 DE DE60205888T patent/DE60205888T2/de not_active Expired - Fee Related
- 2002-04-26 JP JP2002589481A patent/JP4137645B2/ja not_active Expired - Fee Related
- 2002-04-26 ES ES02724553T patent/ES2245731T3/es not_active Expired - Lifetime
- 2002-04-26 WO PCT/IB2002/001450 patent/WO2002092597A1/fr not_active Ceased
- 2002-04-26 AT AT02724553T patent/ATE303386T1/de not_active IP Right Cessation
- 2002-04-26 HR HR20030911A patent/HRP20030911A2/xx not_active Application Discontinuation
- 2002-04-26 EP EP02724553A patent/EP1390366B1/fr not_active Expired - Lifetime
- 2002-04-26 KR KR10-2003-7014752A patent/KR20040008175A/ko not_active Ceased
- 2002-04-26 CZ CZ20032917A patent/CZ20032917A3/cs unknown
- 2002-05-06 US US10/139,449 patent/US6787549B2/en not_active Expired - Fee Related
- 2002-05-09 AP APAP/P/2002/002522A patent/AP1429A/en active
- 2002-05-09 GT GT200200081A patent/GT200200081A/es unknown
- 2002-05-10 PE PE2002000392A patent/PE20021095A1/es not_active Application Discontinuation
- 2002-05-13 AR ARP020101735A patent/AR035889A1/es unknown
- 2002-05-13 UY UY27287A patent/UY27287A1/es not_active Application Discontinuation
- 2002-05-13 MY MYPI20021725A patent/MY134123A/en unknown
- 2002-05-14 PA PA20028545001A patent/PA8545001A1/es unknown
2003
- 2003-07-08 TN TNPCT/IB2002/001450A patent/TNSN03112A1/fr unknown
- 2003-09-15 IS IS6956A patent/IS6956A/is unknown
- 2003-09-16 ZA ZA200307234A patent/ZA200307234B/en unknown
- 2003-11-10 MA MA27390A patent/MA27021A1/fr unknown
- 2003-11-11 BG BG108344A patent/BG108344A/bg unknown
- 2003-11-13 NO NO20035035A patent/NO20035035D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AP2002002522A0 (en)	2002-06-30
DOP2002000390A (es)	2003-03-15
AR035889A1 (es)	2004-07-21
US6787549B2 (en)	2004-09-07
UY27287A1 (es)	2003-02-28
HUP0304085A3 (en)	2005-09-28
EP1390366A1 (fr)	2004-02-25
OA12600A (en)	2006-06-09
EP1390366B1 (fr)	2005-08-31
KR20040008175A (ko)	2004-01-28
BG108344A (bg)	2004-12-30
IL157874A0 (en)	2004-03-28
EE200300557A (et)	2004-04-15
WO2002092597A1 (fr)	2002-11-21
GT200200081A (es)	2003-04-22
HUP0304085A2 (en)	2004-04-28
IS6956A (is)	2003-09-15
CN1509288A (zh)	2004-06-30
MXPA03010365A (es)	2004-03-16
HRP20030911A2 (en)	2004-02-29
JP2004529186A (ja)	2004-09-24
NO20035035L (no)	2003-11-13
SK13372003A3 (sk)	2004-08-03
ZA200307234B (en)	2004-09-16
NO20035035D0 (no)	2003-11-13
ES2245731T3 (es)	2006-01-16
US20030149091A1 (en)	2003-08-07
EA200301120A1 (ru)	2004-02-26
PL366774A1 (en)	2005-02-07
PA8545001A1 (es)	2003-09-05
PE20021095A1 (es)	2002-12-14
CA2446988A1 (fr)	2002-11-21
DZ3503A1 (fr)	2002-11-21
JP4137645B2 (ja)	2008-08-20
TNSN03112A1 (fr)	2005-12-23
EA005529B1 (ru)	2005-04-28
MY134123A (en)	2007-11-30
DE60205888T2 (de)	2006-07-06
CZ20032917A3 (cs)	2004-07-14
ATE303386T1 (de)	2005-09-15
AP1429A (en)	2005-06-13
UA73421C2 (en)	2005-07-15
NZ528209A (en)	2004-09-24
DE60205888D1 (de)	2005-10-06

Publication	Publication Date	Title
MA27020A1 (fr)	2004-12-20	Sels consistant en tartrates de 5,8,14-triazatetracyclo (10.3.1.0 .0)-hexadeca-2(11),3,5,7,9-pentaene et compositions pharmaceutiques les contenant.
MA27021A1 (fr)	2004-12-20	Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant
EP1781257A4 (fr)	2012-06-20	Formulations pharmaceutiques contenant des microparticules ou des nanoparticules d'un agent d'administration
NO20042739L (no)	2004-07-23	Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
FR2805818B1 (fr)	2002-04-26	Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
PL357144A1 (pl)	2004-07-12	Nowe postaci dawki podstawionego benzimidazolu oraz sposoby ich zastosowania
CA2452577A1 (fr)	2003-01-16	Capsules molles
MY144992A (en)	2011-12-15	Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MXPA05013637A (es)	2006-02-24	Inhibidores gsk-3 y usos de los mismos.
ITRM990338A0 (it)	1999-05-28	Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
IL170120A (en)	2013-04-30	4,2,1 - Triazines, their use in the preparation of HIV treatment or prophylaxis drugs, containing pharmaceutical preparations and methods for their preparation
IL161326A0 (en)	2004-09-27	Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
TW200509992A (en)	2005-03-16	Dosage form containing pantoprazole as active ingredient
ITRM20030363A1 (it)	2005-01-25	Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
WO2004098577A3 (fr)	2004-12-09	Forme posologique contenant du (s)-pantoprazole en tant qu'ingredient actif
WO2002096870A3 (fr)	2003-08-07	Terpenoides derives de l'eponge et procedes d'utilisation
PL368040A1 (en)	2005-03-21	Substituted 4-aminocyclohexanol derivatives
EP1697335A4 (fr)	2010-07-07	Derives de furancarbonylguanidine, leur preparation et compositions pharmaceutiques les contenant
RU2002121504A (ru)	2004-03-20	Лекарственные средства для лечения дегенеративного артрита
FR2826651B1 (fr)	2005-09-02	Forme cristalline d'une phenylethanolamine, sa preparation et compositions pharmaceutiques la contenant
FR2843301B1 (fr)	2004-10-22	Forme galenique pour la delivrance colique de principes actifs
HRP20070441T3 (hr)	2007-10-31	Farmaceutska kombinacija za liječenje grčeva i/ili boli
RU2000113775A (ru)	2002-04-27	Препарат для профилактики и лечения эндометрита
SE9902674D0 (sv)	1999-07-12	New composition
TH82489B (th)	2007-01-18	สูตรผสมของมอกซิฟลอกซาซิน/โซเดียม คลอไรด์